Abstract
On the basis of the hypothesis that the opiate-like neuropeptides, such as beta-endorphin, may be involved in the etiology of schizophrenic symptoms, naloxone 1.2 mg and placebo were administered intravenously to 8 schizophrenic patients, using a double-blind, crossover design. Naloxone was not found to be different from placebo in effecting schizophrenic symptoms, including hallucinations and delusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bloom, F., Segal, D., Ling, N., Guillemin, R.: Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194, 630–632 (1976)
Cox, B., Ary, M., Lomax, P.: Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats. J. Pharmacol. exp. Ther. 196, 637–641 (1976)
Gunne, L., Lindstrom, L., Terenius, L. M.: Naloxone-induced reversal of schizophrenic hallucinations. J. Neurotrans. (in press, 1977)
Holtzman, S. G.: Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J. Pharmacol. exp. Ther. 189, 51–60 (1974)
Jacquet, Y. S., Marks, N.: The C-fragment of beta-Lipotropin: An endogenous neuroleptic or antipsychotogen. Science 194, 632–635 (1976)
McMillan, D. E.: Interactions between naloxone and chlorpromazine on behavior under schedule control. Psychopharmacologia (Berl.) 19, 128–133 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Janowsky, D.S., Segal, D.S., Abrams, A. et al. Negative naloxone effects in schizophrenic patients. Psychopharmacology 53, 295–297 (1977). https://doi.org/10.1007/BF00492367
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00492367